Lv51
1140 积分 2025-06-05 加入
Antibody–Bottlebrush Conjugates Unlock Diverse Payloads for Targeted Cancer Therapy
1小时前
待确认
Challenges and approaches to the design of hydrophilic linkers for antibody-drug conjugates
4小时前
待确认
Targeting key epigenetic regulators in solid tumors: focus on EZH2, PRMT5, and BET inhibitors
3个月前
已完结
Chromatin remodellers as therapeutic targets
3个月前
已完结
Preclinical pharmacokinetics and metabolism of MAK683, a clinical stage selective oral embryonic ectoderm development (EED) inhibitor for cancer treatment
5个月前
已完结
Recent update on the development of EZH2 inhibitors and degraders for cancer therapy
5个月前
已完结
MK-0457, an Aurora kinase and BCR–ABL inhibitor, is active in patients with BCR–ABL T315I leukemia
9个月前
已完结
Free energy perturbation in the design of EED ligands as inhibitors of polycomb repressive complex 2 (PRC2) methyltransferase
1年前
已完结
Recent Progress in DNA Damage Response-Targeting PROTAC Degraders
1年前
已完结
Design and Application of Cereblon-Recruiting Prodegraders
1年前
已完结
皖公网安备34019202002308
